Myeloma Research To Be Presented At The American Society of Clinical Oncology's 47th Annual Meeting (ASCO 2011)

May 27, 2011

Dr. Jesus Berdeja to present results from a Phase 1 study of lorvotuzumab mertansine in combination with Revlimid and dexamethasone in a specific subset of relapsed / refractory myeloma patients whose myeloma cells contain the CD56 protein.

Please click here for more details.